Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Autoimmune Disorders

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 172 articles:
HTML format
Text format



Single Articles


    May 2017
  1. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed     Text format    


  2. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed     Text format    


  3. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  4. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  5. TIMMINGS PL, Siu R, Bukhari W, Todd A, et al
    Author response: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874-1875.
    PubMed     Text format    


  6. GERARDIN P, Cao-Lormeau VM, Tournebize P, Cerny T, et al
    Letter re: Acute Zika infection with concurrent onset of Guillain-BarrE syndrome.
    Neurology. 2017;88:1874.
    PubMed     Text format    


  7. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Text format     Abstract available


  8. AUBERT-BROCHE B, Weier K, Longoni G, Fonov VS, et al
    Monophasic demyelination reduces brain growth in children.
    Neurology. 2017;88:1744-1750.
    PubMed     Text format     Abstract available


  9. GAIG C, Graus F, Compta Y, Hogl B, et al
    Clinical manifestations of the anti-IgLON5 disease.
    Neurology. 2017;88:1736-1743.
    PubMed     Text format     Abstract available


    April 2017
  10. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Text format     Abstract available


  11. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Text format     Abstract available


  12. NUNLEY KA, Leckie RL, Orchard TJ, Costacou T, et al
    Physical activity and hippocampal volume in middle-aged patients with type 1 diabetes.
    Neurology. 2017;88:1564-1570.
    PubMed     Text format     Abstract available


  13. MADDISON P, Gozzard P, Grainge MJ, Lang B, et al
    Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome.
    Neurology. 2017;88:1334-1339.
    PubMed     Text format     Abstract available


    March 2017
  14. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Text format     Abstract available


  15. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Text format     Abstract available


  16. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Text format     Abstract available


  17. TORRES-VEGA E, Mancheno N, Cebrian-Silla A, Herranz-Perez V, et al
    Netrin-1 receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis.
    Neurology. 2017 Mar 1. pii: 10.1212/WNL.0000000000003778.
    PubMed     Text format     Abstract available


    February 2017
  18. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Text format     Abstract available


  19. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Text format     Abstract available


  20. SIDHOM Y, Maillart E, Tezenas du Montcel S, Kacem I, et al
    Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003762.
    PubMed     Text format     Abstract available


  21. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  22. MOLKO N, Simon O, Guyon D, Biron A, et al
    Zika virus infection and myasthenia gravis: Report of 2 cases.
    Neurology. 2017 Feb 10. pii: 10.1212/WNL.0000000000003697.
    PubMed     Text format    


  23. EIJLERS AJ, Meijer KA, Wassenaar TM, Steenwijk MD, et al
    Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003689.
    PubMed     Text format     Abstract available


  24. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  25. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  26. FILLI L, Zorner B, Kapitza S, Reuter K, et al
    Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003656.
    PubMed     Text format     Abstract available


  27. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  28. SANDERS DB, Wolfe GI, Narayanaswami P
    Author response: International consensus guidance for management of myasthenia gravis: Executive summary.
    Neurology. 2017;88:505-506.
    PubMed     Text format    


  29. LI HF, Xie Y, Hong Y
    Letter re: International consensus guidance for management of myasthenia gravis: Executive summary.
    Neurology. 2017;88:505.
    PubMed     Text format    


  30. PASNOOR M
    Author response: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2017;88:417-418.
    PubMed     Text format    


  31. KELKAR P
    Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2017;88:417.
    PubMed     Text format    


  32. HECKMANN JM, Bateman K
    Letter re: A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2017;88:417.
    PubMed     Text format    


  33. SCHEIBE F, Pruss H, Mengel AM, Kohler S, et al
    Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
    Neurology. 2017;88:366-370.
    PubMed     Text format     Abstract available


  34. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Text format     Abstract available


  35. BARGIELA D, Bianchi MT, Westover MB, Chibnik LB, et al
    Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology. 2017 Jan 13. pii: 10.1212/WNL.0000000000003612.
    PubMed     Text format     Abstract available


  36. BUTTON J, Al-Louzi O, Lang A, Bhargava P, et al
    Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003582.
    PubMed     Text format     Abstract available


  37. MASSEY TH, Smith R, Sadiq S, Overton C, et al
    Rescue of severe brain and cervical cord IRIS by restarting natalizumab in a pregnant MS patient.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003604.
    PubMed     Text format    


  38. DO LD, Chanson E, Desestret V, Joubert B, et al
    Characteristics in limbic encephalitis with anti-adenylate kinase 5 autoantibodies.
    Neurology. 2017 Jan 6. pii: 10.1212/WNL.0000000000003586.
    PubMed     Text format     Abstract available


    December 2016
  39. URUHA A, Nishikawa A, Tsuburaya RS, Hamanaka K, et al
    Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.
    Neurology. 2016 Dec 30. pii: 10.1212/WNL.0000000000003568.
    PubMed     Text format     Abstract available


  40. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Text format     Abstract available


  41. GOEDEE HS, van der Pol WL, van Asseldonk JH, Franssen H, et al
    Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.
    Neurology. 2016 Dec 7. pii: 10.1212/WNL.0000000000003483.
    PubMed     Text format     Abstract available


    November 2016
  42. NIELSEN NM, Munger KL, Koch-Henriksen N, Hougaard DM, et al
    Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003454.
    PubMed     Text format     Abstract available


  43. KIM DD, Budhram A, Pelz D, MacDonald M, et al
    Teaching NeuroImages: Orbital infarction syndrome from giant cell arteritis.
    Neurology. 2016;87:e269.
    PubMed     Text format    


  44. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed     Text format    



  45. Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:2284.
    PubMed     Text format    


  46. DALE RC, Brenton JN
    Maternal autoimmunity is a risk factor for common neurologic diseases of childhood.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003440.
    PubMed     Text format    


  47. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    



  48. Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87:2068.
    PubMed     Text format    


  49. DIMACHKIE MM, Abuzinadah AR, Barohn RJ, Oskarsson B, et al
    Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Neurology. 2016;87:2067-2068.
    PubMed     Text format    


  50. ESHAGHI A, Wottschel V, Cortese R, Calabrese M, et al
    Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003395.
    PubMed     Text format     Abstract available


    October 2016
  51. BOLDINGH MI, Maniaol AH, Brunborg C, Weedon-Fekjaer H, et al
    Increased risk for clinical onset of myasthenia gravis during the postpartum period.
    Neurology. 2016 Oct 21. pii: 10.1212/WNL.0000000000003339.
    PubMed     Text format     Abstract available


  52. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


  53. SALZER J, Svenningsson R, Alping P, Novakova L, et al
    Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003331.
    PubMed     Text format     Abstract available


  54. GIOVANNONI G, Cohen JA, Coles AJ, Hartung HP, et al
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003319.
    PubMed     Text format     Abstract available


    September 2016
  55. DORANS KS, Massa J, Chitnis T, Ascherio A, et al
    Physical activity and the incidence of multiple sclerosis.
    Neurology. 2016 Sep 28. pii: 10.1212/WNL.0000000000003260.
    PubMed     Text format     Abstract available


  56. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed     Text format    


  57. COTTER J, Firth J, Enzinger C, Kontopantelis E, et al
    Social cognition in multiple sclerosis: A systematic review and meta-analysis.
    Neurology. 2016 Sep 21. pii: 10.1212/WNL.0000000000003236.
    PubMed     Text format     Abstract available


  58. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  59. BOVE R, White CC, Fitzgerald KC, Chitnis T, et al
    Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003176.
    PubMed     Text format     Abstract available


  60. VOSKUHL R, Patti F
    Hormone replacement in menopausal women with multiple sclerosis: Looking back, thinking forward.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003189.
    PubMed     Text format    


  61. PANZER JA, Lyons JA
    Autoimmune encephalitis in the age of neuronal surface antigens.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003187.
    PubMed     Text format    


  62. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    August 2016
  63. SOLOMON AJ, Bourdette DN, Cross AH, Applebee A, et al
    The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2016 Aug 31. pii: 10.1212/WNL.0000000000003152.
    PubMed     Text format     Abstract available


  64. GHEZZI A, Amato MP, Makhani N, Shreiner T, et al
    Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  65. BANWELL B, Arnold DL, Tillema JM, Rocca MA, et al
    MRI in the evaluation of pediatric multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  66. AMATO MP, Krupp LB, Charvet LE, Penner I, et al
    Pediatric multiple sclerosis: Cognition and mood.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  67. WALDMAN A, Ness J, Pohl D, Simone IL, et al
    Pediatric multiple sclerosis: Clinical features and outcome.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  68. HINTZEN RQ, Dale RC, Neuteboom RF, Mar S, et al
    Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  69. KRUPP LB, Rintell D, Charvet LE, Milazzo M, et al
    Pediatric multiple sclerosis: Perspectives from adolescents and their families.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  70. CHITNIS T, Ghezzi A, Bajer-Kornek B, Boyko A, et al
    Pediatric multiple sclerosis: Escalation and emerging treatments.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available



  71. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2016;87:960.
    PubMed     Text format    


  72. SCHWAB N, Schneider-Hohendorf T, Wiendl H, Cahir-McFarland E, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2016;87:958-9.
    PubMed     Text format    


  73. CAHIR-MCFARLAND E, Ransohoff RM, Lieberman L, Plavina T, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Author Response.
    Neurology. 2016;87:958-9.
    PubMed     Text format    


  74. BANWELL B
    Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:822-6.
    PubMed     Text format    


  75. KHALIL M, Salzer J
    CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Neurology. 2016 Aug 12. pii: 10.1212/WNL.0000000000003107.
    PubMed     Text format    



  76. Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;87:646.
    PubMed     Text format    


  77. JONES DE, Sutliff MH, Halper J, Armstrong MJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2016;87:646.
    PubMed     Text format    


  78. QUIROGA AC, Sabatino JJ Jr, Zee DS, Gold DR, et al
    Teaching Video NeuroImages: The hopping lid twitch in myasthenia gravis.
    Neurology. 2016;87:e55.
    PubMed     Text format    


    July 2016
  79. PURCHIARONI F, Salvetti M, Buscarinu MC, Annibale B, et al
    Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003045.
    PubMed     Text format    


  80. BENOIT A, Durand-Dubief F, Amato MP, Portaccio E, et al
    History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003036.
    PubMed     Text format     Abstract available


  81. GILMORE W, Airas L
    Successive pregnancies in multiple sclerosis.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003039.
    PubMed     Text format    


  82. SIU R, Bukhari W, Todd A, Gunn W, et al
    Acute Zika infection with concurrent onset of Guillain-Barre Syndrome.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003038.
    PubMed     Text format    


  83. GOLAN D, Miller A, Sotirchos ES, Bhargava P, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:446.
    PubMed     Text format    


  84. AVASARALA J, Sotirchos ES, Bhargava P, Calabresi PA, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:445-6.
    PubMed     Text format    


  85. PREZIOSA P, Comi G, Filippi M
    Optic neuritis in multiple sclerosis: Looking from a patient's eyes.
    Neurology. 2016;87:338-9.
    PubMed     Text format    


  86. FERREIRA DA SILVA IR, Frontera JA, Moreira do Nascimento OJ
    News from the battlefront: Zika virus-associated Guillain-BarrE Syndrome in Brazil.
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000003024.
    PubMed     Text format    


  87. MILLER AE, Pelletier D
    Multiple sclerosis: Rapid diagnosis or right diagnosis?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002994.
    PubMed     Text format    


  88. BARNETT C, Bril V, Kapral M, Kulkarni A, et al
    Development and validation of the Myasthenia Gravis Impairment Index.
    Neurology. 2016 Jul 8. pii: 10.1212/WNL.0000000000002971.
    PubMed     Text format     Abstract available


  89. DALE RC, Lim M
    The origins and progression of CNS autoimmunity: Nature, nurture, and tumor.
    Neurology. 2016 Jul 6. pii: 10.1212/WNL.0000000000002959.
    PubMed     Text format    


    June 2016
  90. WANG G, Marrie RA, Salter AR, Fox R, et al
    Health insurance affects the use of disease-modifying therapy in multiple sclerosis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002887.
    PubMed     Text format     Abstract available


  91. SANDERS DB, Wolfe GI, Benatar M, Evoli A, et al
    International consensus guidance for management of myasthenia gravis: Executive summary.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002790.
    PubMed     Text format     Abstract available


  92. LEHMANN-HORN K, Penkert H, Grein P, Leppmeier U, et al
    PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Neurology. 2016 Jun 24. pii: 10.1212/WNL.0000000000002900.
    PubMed     Text format    


  93. DE FLON P, Gunnarsson M, Laurell K, Soderstrom L, et al
    Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    Neurology. 2016 Jun 17. pii: 10.1212/WNL.0000000000002832.
    PubMed     Text format     Abstract available


  94. DRACHMAN DB
    Methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002818.
    PubMed     Text format    


  95. PASNOOR M, He J, Herbelin L, Burns TM, et al
    A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002795.
    PubMed     Text format     Abstract available


  96. BUTZKUEVEN H, Calabresi PA
    Is my MS patient failing treatment?
    Neurology. 2016 Jun 15. pii: 10.1212/WNL.0000000000002851.
    PubMed     Text format    


    May 2016
  97. KARAMYAN A, Sellner J
    Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;86:e228-30.
    PubMed     Text format    


  98. KOELMAN DL, Chahin S, Mar SS, Venkatesan A, et al
    Acute disseminated encephalomyelitis in 228 patients: A retrospective, multicenter US study.
    Neurology. 2016;86:2085-93.
    PubMed     Text format     Abstract available


  99. SENA A, Capela C, Ferret-Sena V, Munger KL, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2016;86:2026.
    PubMed     Text format    


  100. WATERS PJ, Irani SR
    Neurexin-3alpha: A new antibody target in autoimmune encephalitis.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002781.
    PubMed     Text format    


  101. BUTTMANN M, Seuffert L, Mader U, Toyka KV, et al
    Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002745.
    PubMed     Text format     Abstract available


  102. HYUN JW, Jeong IH, Joung A, Kim SH, et al
    Evaluation of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:1772-9.
    PubMed     Text format     Abstract available


  103. SPATOLA M, Du Pasquier R, Schluep M, Regeniter A, et al
    Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
    Neurology. 2016;86:1780-4.
    PubMed     Text format     Abstract available


  104. KASSAVETIS P, Joseph JB, Francois R, Perloff MD, et al
    Zika virus-associated Guillain-Barre syndrome variant in Haiti.
    Neurology. 2016 May 6. pii: 10.1212/WNL.0000000000002759.
    PubMed     Text format    


  105. TRUINI A, Prosperini L, Calistri V, Fiorelli M, et al
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016 May 4. pii: 10.1212/WNL.0000000000002720.
    PubMed     Text format     Abstract available


  106. VAN SONDEREN A, Schreurs MW, de Bruijn MA, Boukhrissi S, et al
    The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
    Neurology. 2016;86:1692-9.
    PubMed     Text format     Abstract available


  107. MELINYSHYN AN, Gofton TE, Schulz V
    Supernumerary phantom limbs in ICU patients with acute inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:1726-8.
    PubMed     Text format     Abstract available


    April 2016
  108. SUMOWSKI JF, Rocca MA, Leavitt VM, Meani A, et al
    Brain reserve against physical disability progression over 5 years in multiple sclerosis.
    Neurology. 2016 Apr 27. pii: 10.1212/WNL.0000000000002702.
    PubMed     Text format     Abstract available


  109. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Text format     Abstract available



  110. Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1465.
    PubMed     Text format    


  111. MCDONNELL GV, Bennett A, Rae-Grant A, Bever C, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  112. BENNETT A, Rae-Grant A, Bever C
    Author Response.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  113. VOLLMER TL, McCarthy M
    Autoimmune encephalitis: A more treatable tragedy if diagnosed early.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002641.
    PubMed     Text format    


  114. LEE WJ, Lee ST, Byun JI, Sunwoo JS, et al
    Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort.
    Neurology. 2016 Apr 1. pii: 10.1212/WNL.0000000000002635.
    PubMed     Text format     Abstract available


    March 2016
  115. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Text format     Abstract available


  116. HOBSON-WEBB LD
    Comment: Is 3,4-DAP a new option in treating MuSK MG?
    Neurology. 2016;86:1071.
    PubMed     Text format    


  117. GRANT WB, Riise T
    Multiple sclerosis: A lifestyle disease?
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002487.
    PubMed     Text format    


  118. BERRIGAN LI, Fisk JD, Patten SB, Tremlett H, et al
    Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002564.
    PubMed     Text format     Abstract available


  119. MARRIE RA, Patten SB, Tremlett H, Wolfson C, et al
    Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002481.
    PubMed     Text format     Abstract available


  120. O'CONNOR P, Comi G, Freedman MS, Miller AE, et al
    Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    Neurology. 2016;86:920-30.
    PubMed     Text format     Abstract available


  121. ZHANG T, Tremlett H, Leung S, Zhu F, et al
    Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Neurology. 2016 Mar 4. pii: 10.1212/WNL.0000000000002543.
    PubMed     Text format     Abstract available


  122. GONZALEZ-PEREZ P, Correia M, Capizzano AA, Adams HP, et al
    Isolated cortical vein thrombosis in autoimmune polyglandular syndrome type 2.
    Neurology. 2016 Mar 2. pii: 10.1212/WNL.0000000000002530.
    PubMed     Text format    


  123. DALAKAS MC, Gooch C
    Close to the node but far enough: What nodal antibodies tell us about CIDP and its therapies.
    Neurology. 2016;86:796-7.
    PubMed     Text format    


  124. DEVAUX JJ, Miura Y, Fukami Y, Inoue T, et al
    Neurofascin-155 IgG4 in chronic inflammatory demyelinating polyneuropathy.
    Neurology. 2016;86:800-7.
    PubMed     Text format     Abstract available


    February 2016
  125. BARBIN L, Rousseau C, Jousset N, Casey R, et al
    Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology. 2016;86:771-8.
    PubMed     Text format     Abstract available


  126. LOPEZ-CHIRIBOGA AS, Komorowski L, Kumpfel T, Probst C, et al
    Metabotropic glutamate receptor type 1 autoimmunity: Clinical features and treatment outcomes.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002476.
    PubMed     Text format     Abstract available


  127. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    The challenge of comorbidity in clinical trials for multiple sclerosis.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002471.
    PubMed     Text format     Abstract available


  128. DILOKTHORNSAKUL P, Valuck RJ, Nair KV, Corboy JR, et al
    Multiple sclerosis prevalence in the United States commercially insured population.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002469.
    PubMed     Text format     Abstract available


  129. EVOLI A, Alboini PE, Damato V, Iorio R, et al
    3,4-diaminopyridine may improve myasthenia gravis with MuSK antibodies.
    Neurology. 2016 Feb 12. pii: 10.1212/WNL.0000000000002466.
    PubMed     Text format    


  130. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    Recommendations for observational studies of comorbidity in multiple sclerosis.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002474.
    PubMed     Text format     Abstract available


  131. OSKARSSON B, Rocke DM, Dengel K, Richman DP, et al
    Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.
    Neurology. 2016 Feb 5. pii: 10.1212/WNL.0000000000002405.
    PubMed     Text format     Abstract available


  132. CORTESE I, Ohayon J, Fenton K, Lee CC, et al
    Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
    Neurology. 2016 Feb 3. pii: 10.1212/WNL.0000000000002417.
    PubMed     Text format     Abstract available


  133. TAN CT, Mao Z, Qiu W, Hu X, et al
    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
    Neurology. 2016;86:491-2.
    PubMed     Text format    


  134. HAN C, Huang J, Waxman SG
    Sodium channel Nav1.8: Emerging links to human disease.
    Neurology. 2016;86:473-83.
    PubMed     Text format     Abstract available


    January 2016
  135. SHEIKH Z, Jain S, Hillen M
    Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge!
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002450.
    PubMed     Text format    


  136. NERRANT E, Fourcade C, Coulette S, Lechiche C, et al
    Teaching NeuroImages: Extensive vasogenic edema in Bickerstaff brainstem encephalitis.
    Neurology. 2016;86:e38-9.
    PubMed     Text format    


  137. SOUZA PV, Pinto WB, Oliveira AS
    Teaching NeuroImages: Longitudinally extensive transverse myelitis in MELAS.
    Neurology. 2016;86:e37.
    PubMed     Text format    


  138. PRASAD S, Halmagyi GM
    A new test for ocular myasthenia gravis? OMG!
    Neurology. 2016 Jan 20. pii: 10.1212/WNL.0000000000002380.
    PubMed     Text format    


  139. VALKO Y, Rosengren SM, Jung HH, Straumann D, et al
    Ocular vestibular evoked myogenic potentials as a test for myasthenia gravis.
    Neurology. 2016 Jan 20. pii: 10.1212/WNL.0000000000002383.
    PubMed     Text format     Abstract available


  140. BOURRE B, Gueudry J, Lefaucheur R, Borden A, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2016;86:312-3.
    PubMed     Text format    


  141. LINCOLN MR, Schneider R, Hohol M
    Clinical Reasoning: A 34-year-old man with headache, diplopia, and hemiparesis.
    Neurology. 2016;86:e24-8.
    PubMed     Text format    


  142. CHITNIS T, Ness J, Krupp L, Waubant E, et al
    Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
    Neurology. 2016;86:245-52.
    PubMed     Text format     Abstract available


  143. BODINI B, Chard D, Altmann DR, Tozer D, et al
    White and gray matter damage in primary progressive MS: The chicken or the egg?
    Neurology. 2016;86:170-6.
    PubMed     Text format     Abstract available


  144. WAXMAN SG, Kantarci O
    The cerebellar channelopathy of multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002338.
    PubMed     Text format    


  145. ROOSTAEI T, Sadaghiani S, Park MT, Mashhadi R, et al
    Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002326.
    PubMed     Text format     Abstract available


  146. NOUR MM, Nakashima I, Coutinho E, Woodhall M, et al
    Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
    Neurology. 2016;86:79-87.
    PubMed     Text format     Abstract available


  147. UZGIL B, Sherr EH
    Neuroimaging in Aicardi-Goutieres syndrome: Biomarkers for a progressive encephalopathy.
    Neurology. 2016;86:15-6.
    PubMed     Text format    


    December 2015
  148. SOTIRCHOS ES, Bhargava P, Eckstein C, Van Haren K, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002316.
    PubMed     Text format     Abstract available


  149. KIM JK, Kim BJ, Shin HY, Shin KJ, et al
    Acute bulbar palsy as a variant of Guillain-Barre syndrome.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002256.
    PubMed     Text format     Abstract available


  150. LIEBERMAN LA, Zeng W, Singh C, Wang W, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002314.
    PubMed     Text format     Abstract available


  151. MARRIE RA, Fisk JD, Tremlett H, Wolfson C, et al
    Differences in the burden of psychiatric comorbidity in MS vs the general population.
    Neurology. 2015;85:1972-9.
    PubMed     Text format     Abstract available


    November 2015
  152. LAVI E, Gilden D, Nagel M, White T, et al
    Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis.
    Neurology. 2015;85:1914-5.
    PubMed     Text format    


  153. HASELKORN JK, Hughes C, Rae-Grant A, Henson LJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2015;85:1896-903.
    PubMed     Text format     Abstract available


  154. LA PIANA R, Uggetti C, Roncarolo F, Vanderver A, et al
    Neuroradiologic patterns and novel imaging findings in Aicardi-Goutieres syndrome.
    Neurology. 2015 Nov 18. pii: 10.1212/WNL.0000000000002228.
    PubMed     Text format     Abstract available


  155. MABRAY MC, Cha S
    CNS angiitis as a brain tumor mimic with a branching vascular abnormality on T2* MRI.
    Neurology. 2015;85:1819-20.
    PubMed     Text format    


  156. BRADSHAW MJ, Pawate S, Lennon VA, Bloch KC, et al
    Herpes simplex virus 1 encephalitis associated with voltage-gated calcium channel autoimmunity.
    Neurology. 2015 Nov 13. pii: 10.1212/WNL.0000000000002218.
    PubMed     Text format    


  157. HARTUNG DM, Bourdette DN, Ahmed S, Whitham RH, et al
    Author response.
    Neurology. 2015;85:1728.
    PubMed     Text format    


  158. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  159. HARTUNG DM, Bourdette DN, Whitham RH
    Author response.
    Neurology. 2015;85:1727.
    PubMed     Text format    


  160. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  161. DE STEFANO N, Stromillo ML, Giorgio A, Battaglini M, et al
    Long-term assessment of no evidence of disease activity in relapsing-remitting MS.
    Neurology. 2015;85:1722-3.
    PubMed     Text format    


  162. DEBS R, Maillart E, Fahed R, Papeix C, et al
    Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.
    Neurology. 2015;85:1630-2.
    PubMed     Text format    


    October 2015
  163. LOUAPRE C, Govindarajan ST, Gianni C, Langkammer C, et al
    Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002106.
    PubMed     Text format     Abstract available


  164. SYMMONDS M, Leite MI, Schulz UG
    Author's Response:.
    Neurology. 2015;85:1263.
    PubMed     Text format    


  165. TAIEB G, Labauge P
    Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS.
    Neurology. 2015;85:1262-3.
    PubMed     Text format    


  166. BOVE R, Malik MT, Diaz-Cruz C, Chua A, et al
    The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
    Neurology. 2015;85:1209-13.
    PubMed     Text format     Abstract available


  167. LUCAS RM, Banwell B
    Do prenatal sex hormones modulate MS risk?
    Neurology. 2015;85:1193-4.
    PubMed     Text format    


    September 2015
  168. LIU Y, Fu Y, Schoonheim MM, Zhang N, et al
    Structural MRI substrates of cognitive impairment in neuromyelitis optica.
    Neurology. 2015 Sep 30. pii: 10.1212/WNL.0000000000002067.
    PubMed     Text format     Abstract available


  169. LABINER DM
    William A. Sibley, MD (1925-2015).
    Neurology. 2015;85:1016.
    PubMed     Text format    


  170. URREA-MENDOZA E, Kanter D, Revilla FJ, Dornoff E, et al
    Stiff-arm syndrome.
    Neurology. 2015;85:1088-9.
    PubMed     Text format    


    August 2015
  171. SORMANI MP, Evangelou N
    New imaging language skills required in MS.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001978.
    PubMed     Text format    


  172. GASPARD N, Foreman BP, Alvarez V, Cabrera Kang C, et al
    New-onset refractory status epilepticus: Etiology, clinical features, and outcome.
    Neurology. 2015 Aug 21. pii: 10.1212/WNL.0000000000001940.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Autoimmune Disorders is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: